Melatonin suppression of aerobic glycolysis (Warburg effect), survival signalling and metastasis in human leiomyosarcoma

Journal of Pineal Research

Volumn 60, Issue 2, 2016, Pages 167-177

  Mao, Lulu ^a   Dauchy, Robert T ^a   Blask, David E ^a   Dauchy, Erin M ^a   Slakey, Lauren M ^a   Brimer, Samantha ^a   Yuan, Lin ^a   Xiang, Shulin ^a   Hauch, Adam ^a   Smith, Kara ^a   Frasch, Tripp ^a   Belancio, Victoria P ^a   Wren, Melissa A ^a   Hill, Steven M ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

leiomyosarcoma; melatonin; metastasis; signalling pathways; Warburg effect

Indexed keywords

CYCLIC AMP; DNA; GLYCOGEN SYNTHASE KINASE 3BETA; LINOLEIC ACID; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN HYDROLYSATE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA;

ADULT; AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA CONTENT; DNA SYNTHESIS; DRUG BLOOD LEVEL; ENZYME PHOSPHORYLATION; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEIOMYOSARCOMA; METASTASIS INHIBITION; METASTASIS POTENTIAL; NONHUMAN; PERFUSION; RAT; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; METASTASIS; NUDE RAT; PATHOLOGY;

ANIMALS; CELL SURVIVAL; FEMALE; GLYCOLYSIS; HUMANS; LEIOMYOSARCOMA; MELATONIN; NEOPLASM METASTASIS; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84956873099     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12298     Document Type: Article

References (36)

1. Jemal A, Siegal E, Ward E, et al., Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Rodriguez D, Preston MA, Barrisford GW, et al., Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases. Urol Oncol 2014; 32: 958-965.
3. Shirafuji A, Shinagawa A, Kurokawa T, et al., Locally-advanced unresected uterine leiomyosarcoma with triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia: a case report. Oncol Lett 2014; 8: 637-641.
4. Gao CF, Xie Q, Zhang YW, et al., Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther 2009; 8: 2803-2810.
5. Nakamura K, Abarzua F, Hongo A, et al., Hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) are potential targets in uterine leiomyosarcoma. Int J Oncol 2010; 37: 605-614.
6. Zhang YW, Su Y, Lanning N, et al., Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 2005; 24: 101-106.
7. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Ward PS, Thompson CB,. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-307.
9. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-314.
10. Garrido P, Osorio FG, Moran J, et al., Loss of GLUT4 induces metabolic reprogramming and impairs viability of breast cancer cells. J Cell Physiol 2015; 230: 191-198.
11. Hitosugi T, Fan J, Chung TW, et al., Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 2011; 44: 864-877.
12. Rodriguez-Enriquez S, Marin-Hernandez A, Gallardo-Perez JC, et al., Kinetics of transport and phosphorylation of glucose in cancer cells. J Cell Physiol 2009; 221: 552-559.
13. Dauchy RT, Blask DE, Dauchy EM, et al., Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts. J Pineal Res 2009; 47: 32-42.
14. Blask DE,. An overview of the neuroendocrine regulation of experimental tumor growth by melatonin and its analogs and the therapeutic use of melatonin in oncology. In: The Pineal Gland and Cancer, Bartsch C, Bartsch H, Blask DE, et al., eds., Springer-Verlag, Berlin Heidelberg, 2001; pp. 309-335.
15. Dauchy RT, Xiang S, Mao L, et al., Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer. Cancer Res 2014; 74: 4099-4110.
16. Blask DE, Brainard GC, Dauchy RT, et al., Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65: 11174-11184.
17. Mao L, Dauchy RT, Blask DE,. Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3β. Mol Endocrinol 2012; 26: 1808-1820.
18. Hsi LC, Wilson LC, Eling TE,. Opposing effects of 15-lipoxygenase-1 and -2 metabolites on MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol Chem 2002; 277: 40549-40556.
19. Yan D, Avtanksi D, Saxena NK, et al., Leptin-induced epithelial-mesenchymal transition in breast cancer cells requires β-catenin activation via Akt/GSK3- and MTA1/Wnt1 protein-dependent pathways. J Biol Chem 2012; 287: 8598-8612.
20. Brown EN, Choe Y, Shanahan TL, et al., A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol 1997; 272: E506-E516.
21. Hill SM, Blask DE,. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48: 6121-6126.
22. Hill SM, Blask DE, Xiang S, et al., Melatonin and associated signaling pathways that control normal breast epithelium and breast cancer. J Mammary Gland Biol Neoplasia 2011; 16: 235-245.
23. Ran C, Liu H, Hitoshi Y, et al., Proliferation-independent control of tumor glycolysis by PDGFR-mediated AKT activation. Cancer Res 2013; 73: 1831-1843.
24. Xiang S, Dauchy RT, Hauch A, et al., Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. J Pineal Res 2015; 59: 60-69.
25. Mao L, Yuan L, Slakey LM, et al., Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 2010; 12: R107.
26. Danielson LS, Menendex S, Attolinini CS, et al., A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell malignancy. Am J Pathol 2010; 177: 908-917.
27. Hay ED,. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005; 3: 706-720.
28. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
29. Willipinski-Stapelfedt B, Reithdorf S, Assmann V, et al., Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005; 11: 8006-8014.
30. Stamos JL, Weis WI,. The β-catenin destruction complex. Cold Spring Harb Perspect Biol 2013; 5: a007898.
31. Tomaskovic-Crook E, Thompson EW, Thiery JP,. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009; 11: 213.
32. Gilles C, Polette M, Mestdagt M, et al., Transactivation of vimentin by β-catenin in human breast cancer cells. Cancer Res 2003; 63: 2658-2664.
33. Lui VW, Wong EY, Ho K, et al., Inhibition of c-Met down-regulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene 2011; 30: 1127-1134.
34. Kang SW, Lee S, Lee EK,. ROS and energy metabolism in cancer cells: alliance for fast growth. Arch Pharm Res 2015; 38: 338-345.
35. Cheng JC, McBrayer SK, Coarfa C, et al., Expression and phosphorylation of the AS160v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma. Cancer Metab 2013; 1: 14.
36. Blask DE, Dauchy RT, Dauchy EM, et al., Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention. PLoS One 2014; 9: e102776.